CN104474004A - 改善贫血的赖氨酸螯合铁生血素 - Google Patents
改善贫血的赖氨酸螯合铁生血素 Download PDFInfo
- Publication number
- CN104474004A CN104474004A CN201410748199.6A CN201410748199A CN104474004A CN 104474004 A CN104474004 A CN 104474004A CN 201410748199 A CN201410748199 A CN 201410748199A CN 104474004 A CN104474004 A CN 104474004A
- Authority
- CN
- China
- Prior art keywords
- parts
- anemia
- ferrous
- extract
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007502 anemia Diseases 0.000 title claims abstract description 34
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000004472 Lysine Substances 0.000 title abstract 7
- 239000013522 chelant Substances 0.000 title abstract 7
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 title abstract 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 27
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019152 folic acid Nutrition 0.000 claims abstract description 16
- 239000011724 folic acid Substances 0.000 claims abstract description 16
- 229960000304 folic acid Drugs 0.000 claims abstract description 16
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims abstract description 13
- 150000004676 glycans Chemical class 0.000 claims abstract description 13
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 13
- 239000005017 polysaccharide Substances 0.000 claims abstract description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 56
- 241000756943 Codonopsis Species 0.000 claims description 17
- 229910052742 iron Inorganic materials 0.000 claims description 16
- 229930003270 Vitamin B Natural products 0.000 claims description 13
- 235000019156 vitamin B Nutrition 0.000 claims description 13
- 239000011720 vitamin B Substances 0.000 claims description 13
- 229940109275 cyclamate Drugs 0.000 claims description 12
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000019634 flavors Nutrition 0.000 claims description 12
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 229960003646 lysine Drugs 0.000 abstract 6
- 235000018977 lysine Nutrition 0.000 abstract 6
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000009636 Huang Qi Substances 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 abstract 1
- 239000000686 essence Substances 0.000 abstract 1
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- 229960001462 sodium cyclamate Drugs 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000005428 Thiamine Deficiency Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- -1 sitoesterol Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种改善贫血的赖氨酸螯合铁生血素，其特征在于：主要由重量份数的以下组份组成：L-赖氨酸螯合铁80-120份，L赖氨酸盐酸盐500-600份，叶酸2-4份，1％的维生素B125-10份，当归提取物80-120份，党参提取物80-120份，黄氏多糖80-120份，果味香精1-3份，甜蜜素5-15份。本发明采用L赖氨酸螯合铁铁元素能直接吸收、运输，生物学效价高，生血补血作用强，对肠胃无刺激，能改善缺铁性贫血，能预防贫血，增强免疫力。
Description
技术领域
本发明涉及一种改善贫血的赖氨酸螯合铁生血素。
背景技术
缺铁性贫血(iron deficiency anemia,IDA)是由于体内缺少铁质而影响血红蛋白合成所引起的一种常见贫血。在红细胞的产生受到限制之前，体内的铁贮存已耗尽，此时称为缺铁。这种贫血特点是骨髓、肝、脾及其他组织中缺乏可染色铁，血清铁浓度和血清转铁蛋白饱和度均降低。典型病例贫血是属于小细胞低色素型。本病是贫血中常见类型，普遍存在于世界各地。女性缺铁性贫血更为严重。
缺铁性贫血的原因：一是铁的需要量增加而摄入不足，二是铁的吸收不良，三是失血过多等，均会影响血红蛋白和红细胞生存而发生贫血。目前市场上抗贫血的补血剂的主要缺陷是吸收差，对肠胃有一定的刺激。
发明内容
本发明的目的是针对现有技术的不足，提供一种改善铁的吸收、对肠胃无刺激的改善贫血的赖氨酸螯合铁生血素。
本发明的目的是这样实现的：一种改善贫血的赖氨酸螯合铁生血素，其特征在于：主要由重量份数的以下组份组成：
L-赖氨酸螯合铁80-120份，L赖氨酸盐酸盐500-600份，叶酸2-4份，1％的维生素B125-10份，当归提取物80-120份，党参提取物80-120份，黄氏多糖80-120份，果味香精1-3份，甜蜜素5-15份。
采用上述方案采用L赖氨酸螯合铁比采用硫酸亚铁或葡聚糖铁更有利于吸收，铁元素可以直接吸收、运输，生物学效价是其它补铁剂的三倍以上，能有效改善缺铁性贫血、预防贫血。
叶酸对人体的重要营养作用早在1948年即已得到证实，人类如缺乏叶酸可引起巨红细胞性贫血以及白细胞减少症，还会导致身体无力、易怒、没胃口以及精神病症状。叶酸也可预防贫血。
当归提取物含挥发油类成分和有机酸，主要为丁二酸、菸酸、尿嘧啶、腺嘌呤、藁本内酯、维生素B12、维生素E、谷固醇、亚叶酸、丁烯基酞内酯、阿魏酸等。用于补血活血，调经止痛，润肠通便，血虚萎黄，眩晕心悸，月经不调，经闭痛经，虚寒腹痛，肠燥便秘，风湿痹痛，跌扑损伤，痈疽疮疡的植物提取物。
党参提取物补中益气，健脾益肺。用于脾肺虚弱，气短心悸，食少便溏，喘虚咳嗽，内热消渴。
维生素B12用于预防和治疗维生素B1缺乏症，如脚气病﹑神经炎﹑消化不良等。
在上述方案中：主要由重量份数的以下组份组成：
L-赖氨酸螯合铁90-110份，L赖氨酸盐酸盐550-680份，叶酸2.5-3.5份，1％的维生素B126-9份，当归提取物90-110份，党参提取物90-110份，黄氏多糖90-110份，果味香精1.5-2.5份，甜蜜素8-12份。
在上述方案中：主要由重量份数的以下组份组成：
L-赖氨酸螯合铁95-105份，L赖氨酸盐酸盐560-600份，叶酸2.8-3份，1％的维生素B128-9份，当归提取物95-100份，党参提取物95-100份，黄氏多糖95-100份，果味香精2.0-2.5份，甜蜜素8-10份。
在上述方案中：所述当归提取物为当归20:1提取物。
在上述方案中：所述党参提取物为党参20:1提取物。
在上述方案中：将本方制成1g/片的片剂。早晚各服用1片。能起到改善缺铁性贫血的、增强免疫力，预防缺铁性贫血的效果。
本发明的有益效果是：本发明采用L赖氨酸螯合铁铁元素能直接吸收、运输，生物学效价高，生血补血作用强，对肠胃无刺激，能改善缺铁性贫血，能预防贫血，增强免疫力。
具体实施方式
下面结合实施例对本发明做进一步的描述。
实施例1
一种改善贫血的赖氨酸螯合铁生血素，由重量份数的以下组份组成：
L-赖氨酸螯合铁80份，L赖氨酸盐酸盐500份，叶酸2份，1％的维生素B125份，当归(20:1)提取物80份，党参(20:1)提取物80份，黄氏多糖80份，果味香精1份，甜蜜素5份。将以上组份搅拌混合均匀制成1g/片的片剂，早晚各服用一片，对于缺铁性贫血有改善作用，可以预防贫血。
实施例2
一种改善贫血的赖氨酸螯合铁生血素，由重量份数的以下组份组成：
L-赖氨酸螯合铁120份，L赖氨酸盐酸盐600份，叶酸4份，1％的维生素B1210份，当归(20:1)提取物120份，党参(20:1)提取物120份，黄氏多糖120份，果味香精3份，甜蜜素15份。将以上组份搅拌混合均匀制成1g/片的片剂，早晚各服用一片，对于缺铁性贫血有改善作用，可以预防贫血。
实施例3
一种改善贫血的赖氨酸螯合铁生血素，由重量份数的以下组份组成：
L-赖氨酸螯合铁90份，L赖氨酸盐酸盐550份，叶酸2.5份，1％的维生素B126份，当归(20:1)提取物90份，党参(20:1)提取物90份，黄氏多糖110份，果味香精1.5份，甜蜜素8份。将以上组份搅拌混合均匀制成1g/片的片剂，早晚各服用一片，对于缺铁性贫血有改善作用，可以预防贫血。
实施例4
一种改善贫血的赖氨酸螯合铁生血素，由重量份数的以下组份组成：
L-赖氨酸螯合铁110份，L赖氨酸盐酸盐680份，叶酸3.5份，1％的维生素B129份，当归(20:1)提取物110份，党参(20:1)提取物110份，黄氏多糖90份，果味香精2.5份，甜蜜素12份。将以上组份搅拌混合均匀制成1g/片的片剂，早晚各服用一片，对于缺铁性贫血有改善作用，可以预防贫血。
实施例5
一种改善贫血的赖氨酸螯合铁生血素，由重量份数的以下组份组成：
L-赖氨酸螯合铁95份，L赖氨酸盐酸盐560份，叶酸3份，1％的维生素B128份，当归(20:1)提取物100份，党参(20:1)提取物100份，黄氏多糖95份，果味香精2.0份，甜蜜素10份。将以上组份搅拌混合均匀制成1g/片的片剂，早晚各服用一片，对于缺铁性贫血有改善作用，可以预防贫血。
实施例5
一种改善贫血的赖氨酸螯合铁生血素，由重量份数的以下组份组成：
L-赖氨酸螯合铁105份，L赖氨酸盐酸盐600份，叶酸2.8份，1％的维生素B128份，当归(20:1)提取物100份，党参(20:1)提取物100份，黄氏多糖95份，果味香精2.5份，甜蜜素8份。将以上组份搅拌混合均匀制成1g/片的片剂，早晚各服用一片，对于缺铁性贫血有改善作用，可以预防贫血。
Claims (6)
1.一种改善贫血的赖氨酸螯合铁生血素，其特征在于：主要由重量份数的以下组份组成：
L-赖氨酸螯合铁80-120份，L赖氨酸盐酸盐500-600份，叶酸2-4份，1％的维生素B125-10份，当归提取物80-120份，党参提取物80-120份，黄氏多糖80-120份，果味香精1-3份，甜蜜素5-15份。
2.根据权利要求1所述改善贫血的赖氨酸螯合铁生血素，其特征在于：主要由重量份数的以下组份组成：
L-赖氨酸螯合铁90-110份，L赖氨酸盐酸盐550-680份，叶酸2.5-3.5份，1％的维生素B126-9份，当归提取物90-110份，党参提取物90-110份，黄氏多糖90-110份，果味香精1.5-2.5份，甜蜜素8-12份。
3.根据权利要求1所述改善贫血的赖氨酸螯合铁生血素，其特征在于：主要由重量份数的以下组份组成：
L-赖氨酸螯合铁95-105份，L赖氨酸盐酸盐560-600份，叶酸2.8-3份，1％的维生素B128-9份，当归提取物95-100份，党参提取物95-100份，黄氏多糖95-100份，果味香精2.0-2.5份，甜蜜素8-10份。
4.根据权利要求1-3任一项所述改善贫血的赖氨酸螯合铁生血素，其特征在于：所述当归提取物为当归20:1提取物。
5.根据权利要求4所述改善贫血的赖氨酸螯合铁生血素，其特征在于：所述党参提取物为党参20:1提取物。
6.根据权利要求1-3任一项所述改善贫血的赖氨酸螯合铁生血素，其特征在于：将本方制成1g/片的片剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410748199.6A CN104474004A (zh) | 2014-12-09 | 2014-12-09 | 改善贫血的赖氨酸螯合铁生血素 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410748199.6A CN104474004A (zh) | 2014-12-09 | 2014-12-09 | 改善贫血的赖氨酸螯合铁生血素 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104474004A true CN104474004A (zh) | 2015-04-01 |
Family
ID=52748706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410748199.6A Pending CN104474004A (zh) | 2014-12-09 | 2014-12-09 | 改善贫血的赖氨酸螯合铁生血素 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104474004A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1759877A (zh) * | 2004-07-28 | 2006-04-19 | 成都地奥九泓制药厂 | 一种治疗贫血的药物组合物及用途 |
| CN101102762A (zh) * | 2004-12-22 | 2008-01-09 | 药物技术公司 | 含铁组合物 |
| CN103223128A (zh) * | 2012-01-30 | 2013-07-31 | 王凡 | 一种改善营养性贫血的中药组合物及其制备方法 |
-
2014
- 2014-12-09 CN CN201410748199.6A patent/CN104474004A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1759877A (zh) * | 2004-07-28 | 2006-04-19 | 成都地奥九泓制药厂 | 一种治疗贫血的药物组合物及用途 |
| CN101102762A (zh) * | 2004-12-22 | 2008-01-09 | 药物技术公司 | 含铁组合物 |
| CN103223128A (zh) * | 2012-01-30 | 2013-07-31 | 王凡 | 一种改善营养性贫血的中药组合物及其制备方法 |
Non-Patent Citations (6)
| Title |
|---|
| 单安山: "《饲料配置大全》", 31 July 2005 * |
| 张骠等: "《贫血患者吃什么》", 30 April 2005 * |
| 田颖等: ""赖氨酸生理功能的研究进展"", 《美食研究》 * |
| 陈仲铭: "《赛鸽全书》", 31 October 2010 * |
| 顾景范等: "《现代临床营养学》", 31 May 2003, 科学出版社 * |
| 马薇等: ""不同人群缺铁性贫血危险因素探讨"", 《中国临床医生》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103055057B (zh) | 一种与左旋肉碱配伍的植物减肥降脂组合物 | |
| CN107279420A (zh) | 一种压片糖果及其制备方法 | |
| CN103849542B (zh) | 一种滋阴补肾保健酒原料、保健酒及其制备方法 | |
| CN103734528B (zh) | 一种羊羔饲料 | |
| CN105233218A (zh) | 一种治疗脾胃虚寒、肠滑作泄的中药组合物 | |
| CN104783033A (zh) | 一种牡蛎深加工复合功能食品 | |
| CN104474004A (zh) | 改善贫血的赖氨酸螯合铁生血素 | |
| CN104304809B (zh) | 泌乳期奶牛饲料添加剂及其应用 | |
| CN103494275B (zh) | 一种娃娃鱼的汤煲组料 | |
| CN105920125A (zh) | 一种天然低剂量解酒药及制备方法 | |
| CN102657354B (zh) | 一种含有大花红景天的饮料及其制备方法 | |
| CN104208496A (zh) | 一种白冠病的抗病药物 | |
| KR20090070160A (ko) | 해삼용 사료첨가물 | |
| CN103484331B (zh) | 一种保健酒 | |
| CN102671047B (zh) | 一种治疗痤疮、黄褐斑的中药组合物 | |
| CN104815231A (zh) | 一种含六堡茶具有调理胃肠道微生态作用的组合物 | |
| CN104857179A (zh) | 一种改善营养性贫血的中药组合物 | |
| CN110151909A (zh) | 一种复方人参组合提取物的制备和用途 | |
| CN109275898A (zh) | 一种补血养肝膏及其制备方法 | |
| CN107969555A (zh) | 一种哺乳期增强免疫力的母羊饲料 | |
| CN102783570B (zh) | 用于治疗鸭流行性感冒的饲料及其制备方法 | |
| CN109106843A (zh) | 一种治疗肺肿瘤的中药验方 | |
| Wei et al. | Research Progress on Traditional Medicine, Chemical Composition and Pharmacological Activity of Pine Pollen | |
| CN106579228A (zh) | 一种养生汤及其制备方法 | |
| CN101288683A (zh) | 玫瑰茄在制备促进排铅作用保健品中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150401 |
|
| RJ01 | Rejection of invention patent application after publication |